As much as I hate to look too closely at these update PRs, I found that one word very interesting. The ongoing discussions obviously are not how to expand the trial into a new trial, how to change the endpoints to get some significance and not to draw attention to the long hauler trial because the CD12 trial is just not powerful enough. The "conclusion" of discussions is either approve or don't. It is not a word normally used in Cytodyn's PRs, we have been in the process for so long on many indications it is hard to realize this trial is leading to a job done, drug is on the marker result.

As for my theory on what the discussions are, In my opinion they have very little to do with the trial data because it is likely obvious given the mortality endpoint. The discussion is manufacturing and distribution.